During the upcoming 58th annual meeting of the American Society of Hematology, to be held December 3 – 6 in San Diego, CA, multiple corporate and investigator presentations will be featured. This overview (below) presents the key oral and poster presentations to be presented. Also read: ASH 2016: Informative and Clinical Useful.
Additional information and abstracts can be found online at the website of the American Society of Hematology.
| Abstract | Title | Presenter | Type | Time | Location |
|---|---|---|---|---|---|
| Saturday, December 3, 2016 | |||||
| 104 | Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with RCHP as Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B-Cell Lymphoma. [Abstract] | Lihua Budde | Oral | 9:45 a.m. | Room 7AB (San Diego Convention Center) |
| 182 | Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T-Cell Lymphoma Versus Physician’s Choice (Methotrexate or Bexarotene): the Phase 3 ALCANZA Study. [Abstract] | Youn Kim | Oral | 2:15 p.m. | Room 6AB (San Diego Convention Center) |
| 211 | A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia. [Abstract] | Harry Erba | Oral | 4:00 p.m. | San Diego Ballroom AB (Marriott Marquis San Diego Marina) |
| 1606 | Phase II Study of the Salvage Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin (INO) for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). [Abstract] | Koji Sasaki | Poster | 5:30 -7:30 p.m. | Hall GH (San Diego Convention Center) |
| 1645 | Combining IMGN779, a Novel Anti-CD33 Antibody-Drug Conjugate (ADC), with the PARP Inhibitor, Olaparib, Results in Enhanced Anti-Tumor Activity in Preclinical Acute Myeloid Leukemia (AML) Models. [Abstract] | Scott Portwood | Poster | 5:30 -7:30 p.m. | Hall GH (San Diego Convention Center) |
| 1646 | Tumor Specific Glycosylated CD43 Is a Novel and Highly Specific Target for Acute Myeloid Leukemia and Myelodysplastic Syndrome. [Abstract] | Mette Hazenberg | Poster | 5:30 -7:30 p.m. | Hall GH (San Diego Convention Center) |
| 1681 | FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML) [Abstract] | Sophia Adamia | Poster | 5:30 -7:30 p.m. | Hall GH (San Diego Convention Center) |
| 1834 | Safety and Activity of Brentuximab Vedotin plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory Classical Hodgkin Lymphoma: Initial Results of a Phase I/II Trial. [Abstract] | Ryan Cassaday | Poster | 5:30 -7:30 p.m. | Hall GH (San Diego Convention Center) |
| 1841 | ZW38, a Novel Azymetric Bispecific CD19-Directed CD3 T Cell Engager Antibody Drug Conjugate with Controlled T Cell Activation and Improved B Cell Cytotoxicity. [Abstract] | Gordon Ng | Poster | 5:30 -7:30 p.m. | Hall GH (San Diego Convention Center) |
| 1842 | Ninlaro (ixazomib) and Brentuximab Vedotin (ADCETRIS) Combination Results in Synergistic Antitumor Activity in Mouse Models of CD30 Positive Anaplastic Large Cell Lymphoma. [Abstract] | Nibedita Chattopadhyay | Poster | 5:30 -7:30 p.m. | Hall GH (San Diego Convention Center) |
| 1853 | Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study. [Abstract] | Hervé Tilly | Poster | 5:30 -7:30 p.m. | Hall GH (San Diego Convention Center) |
| 1856 | Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study. [Abstract] | Andres Forero-Torres | Poster | 5:30 -7:30 p.m. | Hall GH (San Diego Convention Center) |
| 2368 | Real World Clinical and Economic Burden of Hematopoietic Cell Transplantation Among a Large US Commercially Insured Population. [Abstract] | Neil Josephson | Poster | 5:30 -7:30 p.m. | Hall GH (San Diego Convention Center) |
| Sunday, December 4, 2016 | |||||
| 340 | A Phase 1b Study of Vadastuximab Talirine as Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia. [Abstract] | Jay Yang | Oral | 10:15 a.m. | Pacific Ballroom (Marriott Marquis San Diego Marina) |
| 384 | CD46 Is Amplified in High-Risk Myeloma with Gain of Chromosome 1q and Selectively Targeted By a Novel Anti-CD46 Antibody-Drug Conjugate. [Abstract] | Daniel Sherbenou | Oral | 1:15 p.m. | Grand Hall B (Manchester Grand Hyatt San Diego) |
| 464 | Targeting CD74 with Novel Antibody Drug Conjugates (ADCs) for the Treatment of B-Cell Non-Hodgkin’s Lymphoma (NHL). [Abstract] | Arturo Molina | Oral | 4:45 p.m. | Room 5AB (San Diego Convention Center) |
| 2832 | IMGN632: A CD123-Targeting Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Payload, Is Highly Active and Prolongs Survival in Acute Myeloid Leukemia (AML) Xenograft Models. [Abstract] | Sharlene Adams | Poster | 6:00 – 8:00 p.m. | Hall GH (San Diego Convention Center) |
| 2993 | Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-cell Lymphomas. [Abstract] | Michelle Fanale | Poster | 6:00 – 8:00 p.m. | Hall GH (San Diego Convention Center) |
| 3522 | Novel DNA-Damaging Linker Payloads Are Active in Models of Acquired Resistance to Calicheamicin and Standard of Care. [Abstract] | Jennifer Kahler | Poster | 6:00 – 8:00 p.m. | Hall GH (San Diego Convention Center) |
| 3560 | The Use of a Novel CME Format to Elicit and Develop True Competence in Hematologist Ability to Risk Stratify Patients with Hodgkin Lymphoma. [Abstract] | Patricia Repetto | Poster | 6:00 – 8:00 p.m. | Hall GH (San Diego Convention Center) |
| 3566 | Toxicity Burden of Bleomycin Treatment in Hodgkin Lymphoma: A Systematic Literature Review. [Abstract] | Neil C Josephson | Poster | 6:00 – 8:00 p.m. | Hall GH (San Diego Convention Center) |
| Monday, December 5, 2016 | |||||
| 588 | Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. [Abstract] | Koji Sasaki | Oral | 8:15 a.m. | Marriott Grand 2-4 (Marriott Marquis San Diego Marina) |
| 590 | Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia. [Abstract] | Dale Bixby | Oral | 7:15 a.m. | San Diego Ballroom AB (Marriott Marquis San Diego Marina) |
| 591 | Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients With Acute Myeloid Leukemia. [Abstract] | Amir Fathi | Oral | 7:30 a.m. | San Diego Ballroom AB (Marriott Marquis San Diego Marina) |
| 622 | Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study. [Abstract] | Tycel Phillips | Oral | 7:45 a.m. | Room 6B (San Diego Convention Center) |
| 752 | Inhibition of MDR1 Overcomes Brentuximab Vedotin Resistance in Hodgkin Lymphoma Cell Line Model and Is Synergistic with Brentuximab Vedotin in Mouse Xenograft Model. [Abstract] | Robert Chen | Oral | 10:45 a.m. | Room 6CF (San Diego Convention Center) |
| 768 | A CD123-Targeting Antibody-Drug Conjugate (ADC), IMGN632, Designed to Eradicate Acute Myeloid Leukemia (AML) Cells While Sparing Normal Bone Marrow Cells. [Abstract] | Yelena Kovtun | Oral | 11:45 a.m. | San Diego Ballroom AB (Marriott Marquis San Diego Marina) |
| 1105 | Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. [Abstract] | Alex Herrera | Oral | 4:30 p.m. | Room 6B (San Diego Convention Center) |
| 1106 | A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E). [Abstract] | Catherine Diefenbach | Oral | 4:45 p.m. | Room 6B (San Diego Convention Center) |
| 1109 | Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). [Abstract] | Ramon Garcia-Sanz | Oral | 5:30 p.m. | Room 6B (San Diego Convention Center) |
| 1148 | First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation. [Abstract] | Adam Cohen | Oral | 4:45 p.m. | Hall AB (San Diego Convention Center) |
| 3958 | A New Antibody-Drug Conjugate Composed of an Anti-HLA-DR IgG4 Antibody, IMMU-114, and SN-38, Is Active in Experimental Acute Myelocytic Leukemia (AML), Acute Lymphocytic Leukemia (ALL), and Multiple Myeloma (MM). [Abstract] | Thomas Cardillo | Poster | 6:00 – 8:00 p.m. | Hall GH (San Diego Convention Center) |
| 4126 | Polatuzumab Vedotin; Antibody Drug Conjugates (ADC, anti-CD79b-vc-MMAE, PV) Significantly Enhances in-Vitro Cell Death Against CD79b+ Burkitt Lymphoma (BL) /Primary Mediastinal Large B Cell Lymphoma (PMBL) and Improved Overall Survival Against Rituximab Sensitive/Resistant-BL NSG Xenograft Mice. [Abstract] | Aradhana Awasthi | Poster | 6:00 – 8:00 p.m. | Hall GH (San Diego Convention Center) |
| 4144 | Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. [Abstract] | Barbara Pro | Poster | 6:00 – 8:00 p.m. | Hall GH (San Diego Convention Center) |
| 4146 | A Phase I Trial of TGR-1202, a Next Generation Once-Daily PI3Kδ Inhibitor, in Combination with Brentuximab Vedotin, in Patients with Relapsed/Refractory Hodgkins Lymphoma. [Abstract] | Radhakrishnan Ramchandren | Poster | 6:00 – 8:00 p.m. | Hall GH (San Diego Convention Center) |
| 4154 | A Phase 1/2 Clinical Trial of Brentuximab Vedotin and Bendamustine in Elderly Patients with Previously Untreated Advanced Hodgkin Lymphoma (Halo Study): Preliminary Report. [Abstract] | Andrea Gallamini | Poster | 6:00 – 8:00 p.m. | Hall GH (San Diego Convention Center) |
| 4176 | hLL2-Cys-PBD, a New Site-Specifically Conjugated, Pyrrolobenzodiazepine (PBD) Dimer-Based Antibody Drug Conjugate (ADC) Targeting CD22-Expressing B-Cell Malignancies. [Abstract] | Francesca Zammarchi | Poster | 6:00 – 8:00 p.m. | Hall GH (San Diego Convention Center) |
| 4177 | Denintuzumab Mafodotin Stimulates Immune Responses and Synergizes with CD20 Antibodies to Heighten Anti-Tumor Activity in Preclinical Models of Non-Hodgkin Lymphoma. [Abstract] | Heather Van Epps | Poster | 6:00 – 8:00 p.m. | Hall GH (San Diego Convention Center) |
| 4187 | Identification of Anti-Lymphoma Biomarkers of Response to the Anti-CD37 Antibody Drug Conjugate (ADC) IMGN529. [Abstract] | Francesco Bertoni | Poster | 6:00 – 8:00 p.m. | Hall GH (San Diego Convention Center) |
| 4194 | Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Study. [Abstract] | Alex Herrera | Poster | 6:00 – 8:00 p.m. | Hall GH (San Diego Convention Center) |
| 4225 | CD30 Expression Is Not Acquired at Time of Relapse in Diffuse Large B-Cell Lymphoma. [Abstract] | Oscar Calzada | Poster | 6:00 – 8:00 p.m. | Hall GH (San Diego Convention Center) |
| 4465 | Discovery and Preclinical Development of Novel CD74-Targeting Antibody-Drug Conjugates (ADCs) with Significant Activity in Multiple Myeloma (MM) Cell Lines and Xenograft Models. [Abstract] | Mark Lupher | Poster | 6:00 – 8:00 p.m. | Hall GH (San Diego Convention Center) |
| 4470 | SGN-CD48A: A Novel Humanized Anti-CD48 Antibody-Drug Conjugate for the Treatment of Multiple Myeloma. [Abstract] | Tim Lewis | Poster | 6:00 – 8:00 p.m. | Hall GH (San Diego Convention Center) |
| 4486 | Indatuximab Ravtansine (BT062) in Combination with Low-Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed / Refractory Multiple Myeloma. [Abstract] | Kevin Kelly | Poster | 6:00 – 8:00 p.m. | Hall GH (San Diego Convention Center) |
